AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on AbbVie, with a price target of $222.00. The compan...

AbbVie (ABBV) Gets a Buy from Evercore ISI

With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar...

How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV – Research Report) and Merus (MRUS – Research Report...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Merus (MRUS)

AbbVie’s ($ABBV) shares weakened on Friday, despite the American drugmaker’s third-quarter fiscal year 2025 earnings surpassing Wall Street’s expec...

AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie, with a price target of $280.00. The company’s shares opene...

TD Cowen Remains a Buy on AbbVie (ABBV)

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 1 clinical study titled ‘A Phase 1, Do...

AbbVie’s New Phase 1 Study: A Potential Game Changer?

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A Phase 2, Multicenter, Ran...

AbbVie’s HIV Treatment Study Update: Key Insights for Investors

Abbvie (($ABBV)) announced an update on their ongoing clinical study. Study Overview: AbbVie is conducting a multicenter, open-label study titled ‘...

AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment?

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has completed a Phase 3 clinical study titled ‘A Phase 3 Randomized, P...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$236.28	+2.98%	8.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$236.28	+3.0%	8.02M
3
4
5
6

ABBV

ABBV

No Data Available

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel